Hepatocellular carcinoma
Not yet recruitingPhase 2 Study of Durvalumab + Tremelimumab with Lenvatinib vs Durvalumab + Tremelimumab Alone in Patients with Unresectable Hepatocellular Carcinoma
Phase 2 Study of Durvalumab + Tremelimumab with Lenvatinib vs Durvalumab + Tremelimumab Alone in Patients with Unresectable Hepatocellular Carcinoma
- Disease:Hepatocellular carcinoma
- Substances:DurvalumabLenvatinib+1
Italy- Participants:18–64 years · 65+ years
- Substances:Durvalumab
- Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale








